CDK6 degradation hits Ph1 ALL hard

Abstract

In this issue of Blood, De Dominici et al have identified and tested cyclindependent kinase 6 (CDK6)-selective proteolysis-targeting chimeras (PROTACs) that suppressed Philadelphia chromosome-positive (Ph1) acute lymphoblastic leukemia (ALL) ex vivo and in mice more effectively than approved kinase inhibitors of CDK4/6.